BIOL Biolase Inc

BIOLASE to Showcase Two New Game-Changing Products at International Dental Show in Cologne

BIOLASE, Inc., (NASDAQ: BIOL) the global leader in dental lasers, announced today that it would showcase its two new, game-changing, minimally invasive dental lasers, the Waterlase Express all-tissue laser and the Epic Pro soft-tissue diode laser, at the 37th International Dental Show (IDS) March 21-25 in Cologne, Germany. The show, the world’s largest dental meeting with 2,300 exhibitors from 60 countries, is expected to draw more than 140,000 visitors. IDS is known for its presentations of the latest products, developments and trends in the global dental industry.

The Waterlase Express features the Company’s fifth generation laser technology and represents the new foundation of the Company’s strategy to greatly expand all-tissue laser use in dentistry. It is the industry’s smallest, easiest to use most technologically advanced, customer supportive and affordable dental all-tissue laser system. It was designed with simple, elegant user controls and learning tools so that every dentist, even those new to lasers, can easily learn its capabilities.

The Epic Pro, the first commercially available laser system created in collaboration with IPG Medical Corporation, is the Company’s premium diode laser solution and is unlike anything else on the market. It offers advancements in power, cutting speed, control and precision and allows BIOLASE to access new segments of the market it has not penetrated, including oral and maxillofacial surgery.

BIOLASE President and CEO Harold C. Flynn, Jr. and Holger Arens, the new Vice President and Managing Director for Europe, the Middle East and Africa (EMEA) who is based in Germany, will be among the Company’s executives attending the show and meeting with key distributors and clinicians.

“We believe the international dental market—and in particular Europe and the Middle East, the largest single geographic region in dentistry—represents a tremendous, untapped opportunity for laser dentistry,” Flynn said. “With our two new innovative products now being sold in the US and select international markets, and Holger on the ground building a much stronger and broader presence, we are confident we can reach an entirely new level of market penetration. We are offering the industry a glimpse of dentistry of the future and this conference is an excellent place to showcase our products and the progress we have made as a company. We believe with the addition of these two ground breaking products, we now have lasers for every dentist and that laser dentistry will become the standard of care in modern dentistry.”

BIOLASE will be located in the following stands: German/Intl. Pavilion, Hall 11.3, Stand E050 and US Pavilion, Hall 04.2, Stand L060 M061. Visitors will see a fully interactive exhibition and display, hands-on demonstrations of the laser system portfolio and guest speakers.

To learn more about the Waterlase Express system, the Epic Pro, and other innovations designed to simplify laser dentistry, visit www.biolase.com.

About BIOLASE, Inc.

BIOLASE, Inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment, including digital x-rays and CAD/CAM scanners. BIOLASE’s products are focused on technologies that advance the practice of dentistry to both dentists and their patients. BIOLASE's proprietary laser products incorporate approximately 230 patented and 85 patent-pending technologies designed to provide biologically clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products provide cutting-edge technology at competitive prices to deliver the best results for dentists and patients. BIOLASE's principal products are revolutionary dental laser systems that perform a broad range of dental procedures, including cosmetic and complex surgical applications, and a full line of dental imaging equipment. BIOLASE has sold approximately 33,600 laser systems to date in over 90 countries around the world. Laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer markets.

For updates and information on Waterlase® iPlus™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseinc, LinkedIn at www.linkedin.com/company/biolase, Instagram at www.instagram.com/biolaseinc, and YouTube at www.youtube.com/biolasevideos.

BIOLASE® and Waterlase® are registered trademarks of BIOLASE, Inc.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995

Statements contained in this press release that refer to BIOLASE's estimated or anticipated future results or other non-historical facts are forward-looking statements, as are any statements in this press release concerning prospects related to BIOLASE's strategic initiatives and anticipated financial performance. Forward-looking statements can also be identified through the use of words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “may,” “will,” and variations of these words or similar expressions. Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE's current expectations regarding existing trends, and its strategic initiatives, and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations depending upon a number of factors affecting BIOLASE’s business. These factors include, among others, adverse changes in general economic and market conditions, competitive factors including but not limited to pricing pressures and new product introductions, uncertainty of customer acceptance of new product offerings and market changes, risks associated with managing the growth of the business, and those other risks and uncertainties that may be detailed, from time-to-time, in BIOLASE's reports filed with the SEC. BIOLASE does not undertake any responsibility to revise or update any forward-looking statements contained herein.

EN
20/03/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Biolase Inc

1 director bought

A director at Biolase Inc bought 25,000 shares at 1.671USD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

BIOLASE Announces Expiration of Rights Offering

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that the subscription period for its previously announced rights offering to holders of shares of its common stock expired at 5:00 p.m., Eastern Time, on November 29, 2017, and these rights are no longer exercisable. The Company received basic subscriptions and over-subscriptions for a total of 26,307,719 shares, exceeding the 26,302,703 shares offered in the rights offering. Available shares will be distributed...

 PRESS RELEASE

BIOLASE to Conduct Demos of Portable Waterlase Expressâ„¢ All-Tissue L...

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it will be conducting demonstrations of its recently launched Waterlase Express all-tissue laser system at the Greater New York Dental Meeting next week at the Jacob K. Javits Convention Center. Dr. Samuel B. Low, the company’s chief dental officer, will also be presenting two continuing education workshops at the conference. The sessions will address how dentists can properly incorporate lasers into their practice ...

 PRESS RELEASE

BIOLASE to Present at the Singular Research Best of the Uncovered 12th...

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it is scheduled to present at the Singular Research Best of the Uncovered 12th Annual Conference 2017 on Monday, December 4, 2017, at 3:00 PM Pacific Time. BIOLASE President and Chief Executive Officer Harold C. Flynn, Jr. will be giving the presentation and meeting with investors. The conference is being held at the Hotel Angeleno, 170 North Church Lane, Los Angeles, CA 90049. A live webcast and 90-day rep...

 PRESS RELEASE

BIOLASE Announces Commencement of Rights Offering

IRVINE, Calif.--(BUSINESS WIRE)-- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that it has commenced its previously announced rights offering to holders of shares of its common stock. Under the terms of the rights offering, the Company distributed to its shareholders as of 5:00 p.m., Eastern Time, on November 8, 2017, the record date, 0.346 subscription rights exercisable for each share of the Company’s common stock owned. Each whole subscription right entitles the holder to purchase one s...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch